Updates are available Correction dated 2020-09-07
Click to view Correction: https://doi.org/10.1007/s10637-020-00981-8
-
Authors
Kondo, Shunsuke http://orcid.org/0000-0001-9565-117X
Tajimi, Masaomi
Funai, Tomohiko
Inoue, Koichi
Asou, Hiroya
Ranka, Vinay Kumar
Wacheck, Volker
Doi, Toshihiko
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 7 February 2020
Accepted: 18 June 2020
First Online: 23 June 2020
Change Date: 7 September 2020
Change Type: Correction
Change Details: The article Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer, written by Shunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck, Toshihiko Doi, was originally published electronically on the publisher’s internet portal on 23 June 2020 without open access.
Compliance with ethical standards
:
: Shunsuke Kondo reports research funding from ASLAN Pharmaceuticals, AstraZeneca, Bayer, Eli Lilly, MSD, and Pfizer; Toshihiko Doi reports grants and personal fees from Eli Lilly Japan, Kyowa Hakko Kirin, MSD, Daiichi Sankyo, Sumitomo Dainippon, Taiho, Novartis, Boehringer Ingelheim, Chugai Pharma, Bristol-Myers Squibb, Abbvie, personal fees from Bayer, Rakuten Medical, Ono Pharmaceutical, Astellas Pharma, Oncolys BioPharma, Amgen, Takeda, grants from Merck Serono, Janssen, Pfizer, Quintiles, and Eisai; Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, and Volker Wacheck are employees and shareholders of Eli Lilly and Company. The study was designed under the responsibility of Eli Lilly and Company, in conjunction with the steering committee. The study was funded by Eli Lilly and Company. LY3023414 was provided by Eli Lilly and Company. Eli Lilly and Company collected and analyzed the data and contributed to the interpretation of the study. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was registered at ExternalRef removed as NCT02536586.
: Informed consent was obtained from all individual participants included in the study.
